Trial Profile
Efficacy and safety study of a sustained release dexamethasone intracanalicular insert (Dextenza) in a model of allergic conjunctivitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2017
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Allergic conjunctivitis
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2017 Primary end point (Conjunctival allergen challenge (CAC) reaction to allergen) has not been met as per the results published in the Journal of Ocular Pharmacology and Therapeutics
- 29 Nov 2017 New trial record